Loading…
Lobbying Spend
—
Filings
8
Firms Hired
1
Active Period
2025–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Skin Substitute Access and Payment Reform Act
2026 · third_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5768
Advanced Wound Care and Regenerative Medicine Access and Reform Act
2026 · third_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Client expense: — · Firm income: $60,000
Matched citations: H.R. 6852
Skin Substitute Access and Payment Reform Act of 2025
2026 · third_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). Issues related to skin substitute payment in 2027 Medicare Physician Fee Schedule Proposed Rule (CMS-1848-P) Advanced Wound Care and Regenerative Medicine Access and Reform Act (H.R. 6852)
Client expense: — · Firm income: $60,000
Matched citations: S. 2561
Skin Substitute Access and Payment Reform Act
2026 · second_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5768
Advanced Wound Care and Regenerative Medicine Access and Reform Act
2026 · second_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Client expense: — · Firm income: $60,000
Matched citations: H.R.6852
Skin Substitute Access and Payment Reform Act of 2025
2026 · second_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Client expense: — · Firm income: $60,000
Matched citations: S. 2561
Skin Substitute Access and Payment Reform Act
2026 · first_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5768
Advanced Wound Care and Regenerative Medicine Access and Reform Act
2026 · first_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Client expense: — · Firm income: $60,000
Matched citations: H.R.6852
Skin Substitute Access and Payment Reform Act of 2025
2026 · first_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Client expense: — · Firm income: $60,000
Matched citations: S. 2561
Skin Substitute Access and Payment Reform Act
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5768
Advanced Wound Care and Regenerative Medicine Access and Reform Act
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Client expense: — · Firm income: $60,000
Matched citations: H.R.6852
Skin Substitute Access and Payment Reform Act of 2025
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)
Client expense: — · Firm income: $60,000
Matched citations: S. 2561
Skin Substitute Access and Payment Reform Act of 2025
2025 · third_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Skin Substitute Access and Payment Reform Act of 2025 (S. 2561). Issues related to skin substitute payment in 2026 Physician Fee Schedule Proposed Rule (CMS-1832-P).
Client expense: — · Firm income: $50,000
Matched citations: S. 2561
Source: Senate LDA